About the Chair

Steven R. Grossman, M.D., Ph.D.

Steven R. Grossman, M.D., Ph.D.

Steven R. Grossman, M.D., Ph.D., an internationally recognized expert in gastrointestinal cancers, joined VCU in July 2011 from the University of Massachusetts Medical School in Worcester, Massachusetts. Dr. Grossman received his undergraduate degree from Princeton University and his medical and doctoral degrees from the University of Chicago. He completed a residency in internal medicine at the Harvard Medical School affiliated Brigham and Women’s Hospital in Boston, and completed a fellowship in medical oncology and postdoctoral research training in the laboratory of David Livingston, M.D., at the Dana-Farber Cancer Institute in Boston.

Dr. Grossman, the Deputy Director and Dianne Nunnally Hoppes Endowed Chair in Cancer Research at VCU Massey Cancer Center, is a researcher and physician with specific clinical and research interests in gastrointestinal cancers. He is also an accomplished scientist who currently holds a National Institutes of Health grant to support his research examining the role of tumor suppressor proteins in cancer. Building on this research, he is developing a potentially new way of treating pancreatic cancer.

As deputy director of Massey Cancer Center, Grossman will lead the planning and development of disease-specific scientific research groups; oversee clinical oncology interactions; and develop strategic initiatives in new multidisciplinary research areas. All of these activities are of great importance to the cancer center and will help position Massey for success during the next National Cancer Institute competitive review in 2016, where the center hopes to achieve Comprehensive status, the highest level of NCI Designation.

Dr. Grossman is a past recipient of a Research Scholar Award from the American Cancer Society, the Kimmel Scholar Award from the Sidney Kimmel Foundation for Cancer Research, and a Howard Temin Award in Cancer Research from the National Cancer Institute. Both prestigious grants support the work of researchers advancing the understanding of basic cancer biology and the development of new methods for its prevention and treatment.

Dr. Grossman is Director of the ABIM research track and an active participant on the M.D., Ph.D. Steering Committee and also serves as Medical Director of the Oncology Service Line for the VCU Health System.

Selected Publications

  1. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 2003; 300:342.
  2. Brignone C, Bradley KE, Kisselev AF, Grossman SR. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene. 2004; 23:4121.
  3. Paliwal S, Pande S, Kovi RC, Sharpless NE, Bardeesy N, Grossman SR. Targeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis. Mol Cell Biol. 2006; 26:2360. PMCID: PMC1430274.
  4. Kaur M, Pop M, Shi D, Brignone C, Grossman SR. hHR23B is required for genotoxic-specific activation of p53 and apoptosis. Oncogene. 2007; 26:1231. PMCID: PMC1804095.
  5. Paliwal S, Kovi RC, Nath B, Chen YW, Lewis BC, Grossman SR. The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor. Cancer Res. 2007; 67:9322.
  6. Chen YW, Paliwal S, Draheim K, Grossman SR, Lewis BC. p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res. 2008; 68:476. PMCID: PMC2376045.
  7. Naidu SR, Love IM, Imbalzano AN, Grossman SR, Androphy EJ. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene. 2009; 28:2492. PMCID: PMC2708319.
  8. Shi D, Pop MS, Kulikov R, Love IM, Kung AL, Grossman SR. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci USA. 2009; 106:16275. PMCID: PMC2752525.
  9. Kulikov R, Letienne J, Kaur M, Grossman SR, Arts J, Blattner C. Mdm2 facilitates the association of p53 with the proteasome. Proc Natl Acad Sci USA. 2010; 107:10038. PMCID: PMC2890462.
  10. Kovi RC, Paliwal S, Pande S, Grossman SR. An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ. 2010; 17:513. PMCID: PMC2924672.
  11. Straza MW, Paliwal S, Kovi RC, Rajeshkumar B, Trenh P, Parker D, Whalen GF, Lyle S, Schiffer CA, Grossman SR. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle. 2010; 9:3740. PMCID: PMC3047800.
  12. Shi D, Grossman SR. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther. 2010; 10:737. PMCID: PMC3023568.
  13. Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, Chen S, Zamba KD, Cullen JJ, Meyerholz DK, Meyers S, Davis JN, Grossman SR, Henry MD, Quelle DE. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Mol Cancer Res. 2011; 9:867. PMCID: PMC3140613
  14. Love IM, Sekaric P, Shi D, Grossman SR*, Androphy EJ*.  The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3.  Cell Cycle. 2012; 11:2458-66. (*co-corresponding authors)
  15. Love IM and Grossman SR. It Takes 15 to Tango- Making Sense of the Many Ubiquitin Ligases of p53. Genes Can.  2012; 3:249
  16. Paliwal S Ho N, Parker D, Grossman SR. CtBP2 Promotes Human Cancer Cell Migration by Transcriptional Activation of Tiam1. Genes Cancer. 2012  3:481.
  17. Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP, Deb S. Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. Genes Cancer. 2012 3:491.
  18. Cetin V, Piperdi B, Bathini V, Walsh WV, Yunus S, Tseng JF, Whalen GF, Wassef WY, Kadish SP, Fitzgerald TJ, Mikule C, Wang Y, Grossman SR. A Phase II Trial of Cetuximab, Gemcitabine, 5-Fluorouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma. Gastrointest Cancer Res. 2013 6:S2-9.